In a report issued on February 7, Liisa Bayko from JMP Securities reiterated a Buy rating on Enanta Pharmaceuticals (ENTA), with a price target of $116. The company’s shares closed on Friday at $90.63.
According to TipRanks.com, Bayko is a 5-star analyst with an average return of 15.6% and a 45.1% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Aimmune Therapeutics, and Heron Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Enanta Pharmaceuticals with a $96.25 average price target.
See today’s analyst top recommended stocks >>
Enanta Pharmaceuticals’ market cap is currently $1.76B and has a P/E ratio of 21.94. The company has a Price to Book ratio of 4.47.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ENTA in relation to earlier this year. Last month, Nathaniel Gardiner, the SVP & GC of ENTA bought 2,000 shares for a total of $69,400.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. Its brands include Mavyret and Viekira Pak.
